University of Washington: Lymphoma, Follicular trials

The registry lists 16 Lymphoma, Follicular studies with University of Washington as lead sponsor. 3 are open to participants now and 10 have results posted.

Phase 1 4Phase 2 12No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaRecruitingNCT07731789Phase 2
• Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialRecruitingNCT06948786Phase 2
• Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaRecruitingNCT06442475Phase 2
• Decision Making Tool for Firearm StorageTerminatedNCT06382194Not applicableResults posted
• Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT05169658Phase 2Results posted
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingNCT04257578Phase 1/2Results posted
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative DiseasesTerminatedNCT03498612Phase 2Results posted
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaTerminatedNCT03401853Phase 2Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results posted
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
• Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
• Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
• The "Let's Talk Tech" Tool to Support Decision Making About Technology UseCompletedNCT06817122Not applicable
• Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05453396Phase 2
• Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1